4-ethynyl-1-methyl-1H-imidazole | 55384-94-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-ethynyl-1-methyl-1H-imidazole
• 英文别名: 4-ethynyl-1-methylimidazole
• CAS: 55384-94-6
• 化学式: C₆H₆N₂
• 分子量: 106.127
• InChiKey: KHQAFOOAJHOTDD-UHFFFAOYSA-N

物化性质

• 熔点：
  82-82.5 °C(Solv: carbon tetrachloride (56-23-5))
• 沸点：
  251.1±13.0 °C(Predicted)
• 密度：
  0.93±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-叠氮蒽 、 4-ethynyl-1-methyl-1H-imidazole 在 copper(I) sulfate 、 copper(II) sulfate 、 sodium ascorbate 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 24.0h， 生成 1-(anthracen-2-yl)-4-(1-methyl-1H-imidazol-4-yl)-1H-1,2,3-triazole
  参考文献：
  名称：

  A fluorogenic ‘click’ reaction of azidoanthracene derivatives

  摘要：

  Fluorogenic reactions have broad applications in biolabeling, combinatorial synthesis of fluorescent dyes, and materials development. It was recently reported that the highly selective and efficient Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction can be employed in designing new types of fluorogenic reactions. In this study, we report a fluorogenic reaction using anthracene azides as starting materials. The fluorescence of the anthryl core can be greatly inhibited upon introducing electron-donating azido groups in the proximity. Such weakly fluorescent anthracene azides demonstrate high reactivity with a variety of alkynes under the CuAAC conditions producing a strongly fluorescent triazole product with high quantum yields. This reaction can be used in the synthesis and screening of fluorescent dyes combinatorially. Compared with most existing methods, the fluorogenic CuAAC reaction is a much milder and simpler technique to prepare large libraries of fluorescent dyes without further purification. In order to demonstrate the efficiency of using anthracene azides for biolabeling applications, both small molecules and biomolecules including the multialkyne-derivatized cowpea mosaic virus and tobacco mosaic virus had been studied. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2008.01.080
• 作为产物：
  描述：

  1-methyl-4-((trimethylsilyl)ethynyl)-1H-imidazole 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 以40 %的产率得到4-ethynyl-1-methyl-1H-imidazole
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS PI3KΑ INHIBITORS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME INHIBITEURS DE PI3KΑ

  摘要：

  The present application provides heterocyclic compounds of formula (I) that modulate the activity of the PI3Ka, which are useful in the treatment of various diseases, including cancer.

  公开号：

  WO2023239846A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2015051244A1

  公开（公告）日：2015-04-09

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  调节激酶活性的化合物和药物组合物，包括PI3激酶活性，以及与激酶活性相关的疾病和病况的化合物、药物组合物和治疗方法在此进行描述。
• [EN] HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE TROUBLES MÉDIÉS PAR PI3K-GAMMA
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2015143012A1

  公开（公告）日：2015-09-24

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  本文描述了调节激酶活性的化合物和药物组合物，包括PI3激酶活性，以及与激酶活性相关的疾病和状况的治疗方法，包括PI3激酶活性的化合物、药物组合物和治疗方法。
• TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS
  申请人：Dong-A St Co., Ltd.

  公开号：US20180086709A1

  公开（公告）日：2018-03-29

  The present disclosure relates to a novel tetrahydropyridine derivative compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, methods for preparing the compounds, methods for inhibiting UDP-3-O—(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC), methods for treating Gram-negative bacterial infections, the use of the compounds for the preparation of therapeutic medicaments for treating Gram-negative bacterial infections, and pharmaceutical compositions for prevention or treatment of Gram-negative bacterial infections, which contain the compounds. The compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure can exhibit excellent effects on the treatment bacterial infections.

  本公开涉及一种新型四氢吡啶衍生物化合物，其立体异构体，或其药学上可接受的盐，制备这些化合物的方法，抑制UDP-3-O-(R-3-羟基肉豆蔻酰)-N-乙酰葡萄糖胺脱乙酰酶(LpxC)的方法，治疗革兰氏阴性细菌感染的方法，利用这些化合物制备治疗革兰氏阴性细菌感染的治疗药物的用途，以及包含这些化合物的用于预防或治疗革兰氏阴性细菌感染的药物组合物。根据本公开的公式I所代表的化合物，其立体异构体或药学上可接受的盐可以展现出对治疗细菌感染的优异效果。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20150111874A1

  公开（公告）日：2015-04-23

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  本文描述了调节激酶活性，包括PI3激酶活性的化合物和制药组合物，以及与激酶活性，包括PI3激酶活性相关的疾病和状况的治疗方法、化合物和制药组合物。
• THERAPEUTIC COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160083368A1

  公开（公告）日：2016-03-24

  Compounds of formula I: or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  本发明揭示了化学式I的化合物或其盐。本发明还揭示了包括化合物I的药物组合物，制备化合物I的方法，用于制备化合物I的中间体以及治疗Retroviridae病毒感染，包括HIV病毒感染的治疗方法。